Clinical trials: Proliferative Diabetic Retinopathy (PDR)
Proliferative Diabetic Retinopathy
PRP vs Bevacizumab for PDR Treatment
Protocol S by DRCR.net has shown that receive Ranibizumab as anti-vascular endothelial growth factor (anti-VEGF) therapy with deferred panretinal photocoagulation (PRP) are non-inferior to those in eyes that receive standard…
- Trial name
- NCT02705274
- Testing
- Bevacizumab, Panretinal photocoagulation
- Where
- Syria
- Volunteers
- 30 people
- Sponsor
- Marashi Eye Clinic
High Risk Proliferative Diabetic Retinopathy, Diabetes Mellitus Type I
Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen® (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation and PRP (Monotherapy) in the Treatment With High Risk PDR.
To evaluate the safety and determine the efficacy of PRP monotherapy or combination therapy (pegaptanib 0.3 mg plus PRP) in patients with Type I or Type II diabetes mellitus and with high risk proliferative diabetic retinopathy.
- Conditions
- High Risk Proliferative Diabetic Retinopathy, Diabetes Mellitus Type I, Diabetes Mellitus Type II
- Trial name
- NCT01281098
- Testing
- Panretinal Photocoagulation (PRP), Intravitreous injection of pegaptanib
- Where
- Portugal
- Volunteers
- 22 people
- Sponsor
- Association for Innovation and Biomedical Research on Light and Image
Proliferative Diabetic Retinopathy (PDR)
Laser Photocoagulation and Ranibizumab Treatment in Proliferative Diabetic Retinopathy
To evaluate the effects of PRP as monotherapy or with combination of intravitreal Ranibizumab injection on microvascular density changes of the macula of eyes with PDR using OCTA
- Trial name
- PRP VS PRP&RZB (NCT07819253)
- Testing
- Ranibizumab 0.5 mg, laser photocoagulation (PRP)
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Aswan University
Diabetic Macular Edema, Non-proliferative Diabetic Retinopathy
Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema
The purpose of this study is to test the efficacy of an 0.7 mg intravitreal dexamethasone implant (Ozurdex®) on macular leakage and visual acuity for patients with recalcitrant diabetic macular edema.
- Conditions
- Diabetic Macular Edema, Non-proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy
- Trial name
- NCT01571232
- Testing
- dexamethasone intravitreal implant, intravitreal bevacizumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Retina Macula Institute
Proliferative Diabetic Retinopathy
Intravitreal Bevacizumab vs Laser vs Combination of Bevacizumab and Modified Laser in PDR
In this randomized 3-armed clinical trial, 105 eyes with PDR will be included and divided randomly into 3 groups: IVB group (35 eyes) that receive 4 monthly IVB injections and then rescue IVB, PRP group (35 eyes) that undergo…
- Trial name
- NCT04800679
- Testing
- receive 4 monthly IVB injections and then rescue IVB, PRP group, IVB injections and a modified laser
- Where
- Iran
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Shahid Beheshti University of Medical Sciences
PDR
A Single-Center Trial of Intravitreous Injections of Macugen (Pegaptanib Sodium) Given at Least 7 Days Before Vitrectomy Secondary To Tractional Retinal Detachment in Proliferative Diabetic Retinopathy
Primary objective of this trial will be to evaluate the safety and efficacy of intravitreal injections of Macugen (pegaptanib sodium) when given at least 7-14 days prior to vitrectomy in subjects with tractional retinal…
- Trial name
- NCT01487070
- Testing
- Macugen (Pegaptanib Sodium)
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Retina Institute of Hawaii
Proliferative Diabetic Retinopathy (PDR)
A Study Assessing Efficacy and Safety of OC-10X in the Treatment of PDR
The present study is intended to evaluate the efficacy and safety of topical OC-10X Ophthalmic Suspension in patients diagnosed with proliferative diabetic retinopathy (level 61, 65, 71, or 75). OcuCure Therapeutics, Inc.
- Trial name
- NCT02735369
- Testing
- 2% OC-10X
- Where
- Bangladesh
- Volunteers
- 40 people
- Sponsor
- OcuCure Therapeutics, Inc.
Diabetic Retinopathy
ETDRS PRP With IVR Versus Retinal Photocoagulation Targeted to Ischemic Retina With IVR for the Treatment of PDR
Purpose: To compare panretinal photocoagulation (PRP) as described in ETDRS Study combined with intravitreal injection of ranibizumab (IVR) (ETDRS-PRP group) and retinal photocoagulation targeted to ischemic retina combined with…
- Trial name
- NCT03904056
- Testing
- ISQ-RP, ETDRS-PRP group
- Volunteers
- 23 people
- Sponsor
- São Paulo State University
Proliferative Diabetic Retinopathy
Effect of Postvitrectomy Proactive Use of Conbercept on Postoperative Complications in PDR Patients
This is an unmasking randomized clinical trial. the main purpose of this study is to analyze whether posvitrectomy proactive use of conbercept can reduce the rate of postoperative complication in PDR patients.
- Trial name
- NCT05642793
- Testing
- proactive Anti-VEGF (conbercept) use, passive Anti-VEGF (conbercept) use
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Peking University Third Hospital
Proliferative Diabetic Retinopathy, Age Related Macular Degeneration
Ocular Growth Factors Profile in Proliferative Retinopathies Before and After Intravitreal Bevacizumab
Aims of the trial: Establishing the profile of the growth factors and other mediators of angiogenesis in different ocular fluids (aqueous humour, vitreous gel and ocular liquid in vitrectomized eyes), in the 2 most frequent…
- Trial name
- KIA-ProRet (NCT00776763)
- Testing
- Avastin intravitreal injection
- Where
- Romania
- Volunteers
- 150 people
- Sponsor
- Ophthalmological Association Edelweiss
Diabetic Retinopathy
Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy
The most common ocular disease in patients with diabetes, diabetic retinopathy, is present in approximately 40% of diabetic patients; about 8% of diabetic patients have vision threatening diabetic retinopathy.
- Trial name
- NCT00131144
- Testing
- Octreotide Acetate in Microspheres 20 mg, Octreotide Acetate in Microspheres
- Where
- United States
- Volunteers
- 583 people
- Sponsor
- Novartis
Proliferative Diabetic Retinopathy
Safety and Efficacy of Low-Fluence PRP for PDR
To determine the safety and efficacy of a single session of low-fluence panretinal photocoagulation when compared to full-fluence PRP.
- Trial name
- NCT01737957
- Testing
- Low-fluence PRP with 532nm green LASER, Full-Fluence PRP with 532nm LASER
- Where
- Mexico
- Volunteers
- 60 people
- Sponsor
- Asociación para Evitar la Ceguera en México
Diabetic Retinopathy
Intravitreal Bevacizumab for Management of Active Progressive Proliferative Diabetic Retinopathy (PDR)
To evaluate the effect of intravitreal bevacizumab on the course of diabetic retinopathy in cases with the signs of active progressive PDR
- Trial name
- NCT00370721
- Testing
- bevacizumab
- Where
- Iran
- Sponsor
- Shahid Beheshti University of Medical Sciences
Proliferative Diabetic Retinopathy
25-Gauge Vitrectomy With Ranibizumab or Triamcinolone Acetonide on Proliferative Diabetic Retinopathy in China
Proliferative diabetic retinopathy(PDR) is the leading cause of visual loss in diabetic patients. Operation is an efficient method to treat PDR.
- Trial name
- RaTAPDR (NCT02328118)
- Testing
- Ranibizumab, Triamcinolone Acetonide
- Where
- China
- Volunteers
- 120 people
- Sponsor
- JUNYAN ZHANG
Diabetic Retinopathy
Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy
The most common ocular disease in patients with diabetes, diabetic retinopathy, is present in approximately 40% of diabetic patients; about 8% of diabetic patients have vision threatening diabetic retinopathy.
- Trial name
- NCT00130845
- Testing
- Octreotide Acetate in Microspheres
- Where
- United States
- Volunteers
- 312 people
- Sponsor
- Novartis
Diabetic Retinopathy
Ozurdex in Reducing PVR After Vitreotomy in PDR
Diabetic retinopathy is a significant source of visual morbidity in the adult population. Complications of diabetic retinopathy include ischemic maculopathy, macular edema, and sequelae of fibrovascular proliferation, such as…
- Trial name
- NCT05415826
- Testing
- slow-release dexamethasone implant
- Volunteers
- 30 people
- Sponsor
- Peking University People's Hospital
Proliferative Diabetic Retinopathy, VEGF Overexpression
Day Regimes of CONbercept on CytokinEs of PDR Patients Undergoing Vitrectomy - Trial (CONCEPT)
Patients with proliferative diabetic retinopathy requiring surgical intervention will receive a pre-operative injection of Conbercept.
- Trial name
- CONCEPT (NCT03506750)
- Testing
- IVC, Blood and aqueous humor at the time of IVC, Collect blood, aqueous humor, and initial vitreous at the time of surgery.
- Where
- China
- Volunteers
- 200 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Proliferative Diabetic Retinopathy (PDR)
Multicenter 12 Months Clinical Study to Evaluate Efficacy and Safety of Ranibizumab Alone or in Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone in Proliferative Diabetic Retinopathy (PRIDE)
The purpose of this study was to assess the efficacy and safety of the anti-Vascular Endothelial Growth Factor (VEGF) agent ranibizumab (0.5 mg) with or without Panretinal laser photocoagulation (PRP) compared to PRP alone in…
- Trial name
- PRIDE (NCT01594281)
- Testing
- Ranibizumab 0.5 mg, Panretinal laser photocoagulation
- Where
- 23 sites in Germany
- Volunteers
- 107 people
- Sponsor
- Novartis Pharmaceuticals
Neovascular Glaucoma, Proliferative Diabetic Retinopathy
A Study on the Treatment Strategy of NVG Secondary to PDR
With the increasing incidence of proliferative diabetic retinopathy (PDR), subsequent neovascular glaucoma (NVG) has become one of the main causes of blindness in PDR patients, and the intraocular pressure of PDR patients with…
- Trial name
- NCT05156021
- Testing
- anti-VEGF
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Ruijin Hospital
Proliferative Diabetic Retinopathy (PDR)
Phase I Study Assessing the Ocular and Systemic Safety and Tolerability of OC-10X
The present study is intended to evaluate the safety and tolerability of topical OC-10X Ophthalmic Suspension in healthy human subjects. OcuCure Therapeutics, Inc.
- Trial name
- NCT01869933
- Testing
- OC-10X
- Where
- Bangladesh
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- OcuCure Therapeutics, Inc.